Optiscan Imaging Ltd
ASX:OIL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.072
0.255
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Optiscan Imaging Ltd
Optiscan Imaging Ltd
Cost of Revenue
Optiscan Imaging Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cost of Revenue
-AU$526.2k
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-29%
|
|
|
R
|
Respiri Ltd
ASX:RSH
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ImpediMed Ltd
ASX:IPD
|
Cost of Revenue
-AU$1.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-3%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cost of Revenue
-AU$10.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-10%
|
|
|
Cochlear Ltd
ASX:COH
|
Cost of Revenue
-AU$540.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Optiscan Imaging Ltd
Glance View
Optiscan Imaging Ltd. is engaged in the development of endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The company is headquartered in Mulgrave, Victoria. The firm has developed and commercialized confocal microscopes for clinical and pre-clinical applications. Its endomicroscopic technology enables 3D, in-vivo imaging of human tissue at the cellular level for cancer screening, diagnoses and in surgery. Its InVivage device is developed for clinical use in the oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a miniaturised confocal endomicroscope used for cellular level in-vivo imaging in living tissues. The firm also provides customization options for its product, (FIVE2).
See Also
What is Optiscan Imaging Ltd's Cost of Revenue?
Cost of Revenue
-526.2k
AUD
Based on the financial report for Jun 30, 2024, Optiscan Imaging Ltd's Cost of Revenue amounts to -526.2k AUD.
What is Optiscan Imaging Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-29%
Over the last year, the Cost of Revenue growth was 5%. The average annual Cost of Revenue growth rates for Optiscan Imaging Ltd have been 20% over the past three years , 14% over the past five years , and -29% over the past ten years .
You don't have any saved screeners yet
